Suvadronabinol

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. “Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions,” said Punit Dhillon, CEO of Skye. “In Q2, at our event, ‘Metabolic Rewiring with CB1 Inhibition,’ we outlined our CBeyond™ Phase 2 clinical trial design and highlighted nimacimab’s differentiators, which we believe competitively position Skye. During the second quarter of 2024, we made changes to further support our metabolic focus by adding expertise to our Board of Directors and forming a clinical and scientific advisory board with key opinion leaders. We believe that our uplisting to NASDAQ and strong cash position provide us with the foundation to efficiently execute our Phase 2 obesity clinical trial and build on our strategic vision.” Key Corporate and Clinical Program Highlights Phase 2 Trial in Obesity Expected to Begin in Q3 2024 Nimacimab, is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Skye recently announced its CBeyond™ Phase 2 clinical trial design for nimacimab, for the treatment of obesity. This 120-patient trial is on track to begin screening in Q3 2024 and is expected to provide interim and topline data in Q2 and Q4 of 2025, respectively. The trial’s primary endpoint is to evaluate weight loss using nimacimab compared to placebo.Secondary endpoints include evaluations of safety and tolerability, neuropsychiatric and cognitive evaluation, change in body composition by Dual-Energy X-ray Absorptiometry (DEXA), and changes in key metabolic biomarkers such as triglycerides, insulin and leptin sensitivity.This trial will also be the first to evaluate the combination of a CB1 inhibitor (nimacimab) and a GLP-1 agonist (Wegovy®) in humans in an exploratory arm which will assess the difference in weight loss, the difference in body composition and changes in sleep quality.In connection with the Company’s CBeyond™ trial for nimacimab, Skye announced a collaboration with Beacon Biosignals. Because obesity is recognized as detrimentally affecting sleep quality in some people1, Skye’s CBeyond™ trial will use Beacon Biosignal’s FDA 510(k)-cleared Dreem Headband to collect sleep data and assess validated sleep endpoints in a subset of 40 patients, encompassing all arms of the trial, as an exploratory endpoint. Completion of Glaucoma Study Skye completed a Phase 2a double-masked randomized, placebo-controlled trial of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) in 56 patients with elevated intraocular pressure (IOP) diagnosed with primary open-angle glaucoma or ocular hypertension. The primary endpoint evaluated the change in diurnal IOP in the treated arm vs. placebo over 2 weeks. The study did not achieve a statistically significant improvement in IOP over placebo.Skye has discontinued all clinical development, and research and development related to SBI-100 OE, including its ophthalmology pipeline, and redirected capital resources from its ocular program to its metabolic program. Corporate Highlights Skye recently announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM, to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership expertise to Skye, including over 10 years of board and advisory experience.Skye recently announced the appointment of a new Clinical and Scientific Advisory Board to support the development of nimacimab, with advisors including Lee Kaplan, MD, Ph.D., Louis Aronne, MD, Rekha Kumar, MD, M.S., Marcus DaSilva Goncalves, MD, Ph.D., Beverly Tchang, MD, Eduardo Muñoz, MD, Ph.D. and Giovanni Appendino, Ph.D.Skye uplisted to the NASDAQ Global Market® stock exchange from the OTCQB.Skye was included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the U.S. market open on July 1, 2024, as part of the annual reconstitution of the Russell stock indexes.Subsequent to the end of second quarter, in August, Skye’s convertible debt with a principal balance of $5.0 million was converted into 968,973 shares of the Company’s common stock. Second Quarter 2024 Financial Highlights: Cash Position: Cash and cash equivalents totaled $74.1 million, excluding restricted cash of $9.1 million on June 30, 2024. The Company expects its current cash and cash equivalents to fund projected operations through at least the first half of 2027. R&D Expenses: Research and development (R&D) expenses for the second quarter of 2024 were $4.1 million, as compared to $1.8 million for the same period in 2023. The increase was primarily due to costs associated with the completion of our Phase 2a clinical trial for glaucoma, which has since been discontinued, and the costs from the preparation of the launch of our Phase 2 clinical trial for the treatment of obesity. G&A Expenses: General and administrative (G&A) expenses for the second quarter of 2024 were $4.3 million, as compared to $1.2 million for the same period in 2023. The increase was primarily due to increases in non-cash incentive stock-based compensation, professional services and fees associated with the Company’s January and March 2024 PIPE financings, uplisting to NASDAQ and expansion to support and advance its operations as a publicly-traded company. Net Loss: Net loss for the second quarter of 2024 totaled $7.9 million, with non-cash share-based compensation expense of $1.8 million and non-cash interest expense of $0.3 million, compared to $3.1 million for the second quarter of 2023 with non-cash share-based compensation expense of $0.1 million. 1 Shazia Jehan et al, “Obstructive Sleep Apnea and Obesity: Implications for Public Health,” Sleep Med Disord. 2017; 1(4): 00019. Published online 2017 Dec 12. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: https://www.skyebioscience.com. Connect with us on Twitter and LinkedIn. Forward-looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development for nimacimab, business strategy, the timing of clinical trials for nimacimab, the therapeutic potential of nimacimab and the expected timing through which our current cash and cash equivalents will fund our operating plans. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “expects,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements. SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023Operating expenses Research and development$4,078,751 $1,788,434 $6,025,201 $2,973,314 General and administrative 4,326,820 1,206,405 8,532,620 3,121,683 Estimated legal contingency — (151,842) — (151,842)Total operating expenses 8,405,571 2,842,997 14,557,821 5,943,155 Operating loss (8,405,571) (2,842,997) (14,557,821) (5,943,155) Other (income) expense Interest expense 450,052 186,429 886,988 204,828 Interest income (961,237) (8,598) (1,388,791) (33,112)(Gain) loss from asset sales — — (1,145,141) 307,086 Debt conversion inducement expense — — — 1,383,285 Wind-down costs — 87,072 — 470,181 Other expense (income) 359 — 1,399 (3)Total other (income) expense, net (510,826) 264,903 (1,645,545) 2,332,265 Loss before income taxes (7,894,745) (3,107,900) (12,912,276) (8,275,420)Provision for income taxes 8,071 3,600 10,071 3,600 Net loss$(7,902,816) $(3,111,500) $(12,922,347) $(8,279,020) Loss per common share: Basic$(0.20) $(0.80) $(0.39) $(2.16)Diluted$(0.20) $(0.80) $(0.39) $(2.16) Weighted average shares of common stock outstanding used to compute earnings per share: Basic 38,669,330 3,886,198 33,334,616 3,827,216 Diluted 38,669,330 3,886,198 33,334,616 3,827,216 SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED) June 30,2024 December 31,2023ASSETS Current assets Cash and cash equivalents$74,120,854 $1,256,453 Restricted cash 9,080,202 9,080,202 Prepaid expenses 1,096,039 194,259 Other current assets 2,707,368 1,119,929 Total current assets 87,004,463 11,650,843 Property and equipment, net 45,772 43,276 Operating lease right-of-use asset 202,987 237,983 Other assets 8,309 8,309 Total assets$87,261,531 $11,940,411 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities Accounts payable$1,079,493 $1,155,785 Accrued interest - related party 124,658 126,027 Accrued payroll liabilities 556,573 888,381 Accrued interest - legal contingency 384,896 234,750 Other current liabilities 1,184,795 998,552 Estimate for legal contingency 6,053,468 6,053,468 Convertible note - related party, net of discount 4,859,525 4,371,998 Operating lease liability, current portion 79,165 72,038 Total current liabilities 14,322,573 13,900,999 Non-current liabilities Operating lease liability, net of current portion 129,907 171,230 Total liabilities 14,452,480 14,072,229 Commitments and contingencies (Note 9) Stockholders’ equity (deficit) Preferred stock, $0.001 par value; 200,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2024 and December 31, 2023; 28,067,907 and 12,349,243 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 28,068 12,349 Additional paid-in-capital 190,085,879 102,238,382 Accumulated deficit (117,304,896) (104,382,549)Total stockholders’ equity (deficit) 72,809,051 (2,131,818)Total liabilities and stockholders’ equity (deficit)$87,261,531 $11,940,411 Contacts Investor Relationsir@skyebioscience.com(858) 410-0266 LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889

▲8月15-16日 NDC2024生物医药创新者峰会 扫码立即报名  注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 在2a期试验失败后，Skye Bioscience正在放弃其整个眼病产品线，并转向业内最热门的类别之一——肥胖症。 这家总部位于圣地亚哥的生物技术公司周一宣布，SBI-100没有达到评估原发性开角型青光眼或高眼压患者昼夜眼压的主要终点。这次失败导致其股价在中午下跌了约15%。 今年4月，Skye从场外证券交易所升至纳斯达克。自 8 月以来，它已经筹集了约 1 亿美元。 现在，Skye将把所有资源转向其代谢项目，其中包括其CB1抑制剂nimacimab的2期肥胖研究。该试验预计将于第三季度开始给药，并在 2025 年产生数据。Skye首席执行官Punit Dhillon此前表示，该药物将与一种未命名的GLP-1联合用于一项约200人的研究，该研究将持续26周，外加12周的随访。 该公司表示，停产将使其能够专注于其代谢管线，并将其运营管线延长至2027年。 “去年，我们为我们的代谢计划奠定了基础，目标是使我们的产品组合的疾病靶点和治疗机制多样化，同时显着扩大我们的临床和商业机会，”Dhillon在一份声明中说。 他还在周一表示，该公司认为nimacimab可以提供比行业主导的GLP-1“更高质量，可持续的减肥效果”，GLP-1有自己的一系列问题，如胃肠道副作用和短缺。 版权声明：本文转自生物药大时代 ，如不希望被转载的媒体或个人可与我们联系，我们将立即删除 【关于药融圈】 药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。